{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T20:53:51Z","timestamp":1767905631216,"version":"3.49.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,19]]},"abstract":"<jats:p>This study aimed to elucidate 1-year outcomes following switching to the aflibercept (3\u2009mg) therapy for treatment-resistant wet age-related macular degeneration (wAMD). In this prospective, open-label, non-controlled clinical trial, 18 patients with wAMD who had multiple recurrences or persistent exudation despite intravitreal injections of anti-vascular endothelial growth factor agents (except aflibercept) received a 3-mg intravitreal aflibercept injection every 4 weeks. Each patient received 3 to 8 injections. The central retinal thickness and fibrovascular pigment epithelial detachment height decreased significantly at 1 month after initiation of the aflibercept injection, and the values were 146 and 163.2 \u03bcm, respectively, at the final visit. The morphological improvement was sustained. The intraretinal and subretinal fluid was completely absorbed at the end of the follow-up. The logMAR vision increased from baseline 0.68 to 0.59 (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05). No ocular or systemic adverse events occurred. The intravitreal injection of 3-mg aflibercept seems to be feasible in the treatment of wAMD unresponsive to other anti-vascular endothelial growth factor agents.<\/jats:p>","DOI":"10.1097\/md.0000000000037839","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T18:07:55Z","timestamp":1713550075000},"page":"e37839","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Switching to the aflibercept (3\u2009mg) therapy for treatment-resistant wet age-related macular degeneration: 1-year outcomes"],"prefix":"10.1097","volume":"103","author":[{"given":"Chengcheng","family":"Feng","sequence":"first","affiliation":[{"name":"Qingdao Eye Hospital, Shandong First Medical University, Qingdao, China"},{"name":"State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Shandong Eye Institute, Shandong First Medical University, Qingdao, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Chu","sequence":"additional","affiliation":[{"name":"Qingdao Eye Hospital, Shandong First Medical University, Qingdao, China"},{"name":"State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Shandong Eye Institute, Shandong First Medical University, Qingdao, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Lin","sequence":"additional","affiliation":[{"name":"Qingdao Eye Hospital, Shandong First Medical University, Qingdao, China"},{"name":"State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Shandong Eye Institute, Shandong First Medical University, Qingdao, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Qingdao Eye Hospital, Shandong First Medical University, Qingdao, China"},{"name":"State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Shandong Eye Institute, Shandong First Medical University, Qingdao, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9998-5505","authenticated-orcid":false,"given":"Xiuli","family":"Chen","sequence":"additional","affiliation":[{"name":"Qingdao Eye Hospital, Shandong First Medical University, Qingdao, China"},{"name":"State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Shandong Eye Institute, Shandong First Medical University, Qingdao, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250503","first-page":"1857","article-title":"Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review.","volume":"10","author":"Yang","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00417-014-2838-5","article-title":"Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.","volume":"253","author":"Kawashima","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12886-021-01841-6","article-title":"Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration.","volume":"21","author":"Razavi","year":"2021","journal-title":"BMC Ophthalmol"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1097\/IAE.0000000000001726","article-title":"High-dose high-frequency aflibercept for recalcitrant neovascular age-related macular degeneration.","volume":"38","author":"You","year":"2018","journal-title":"Retina"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects.","volume":"99","author":"Holash","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/bjo.2007.134874","article-title":"Predicted biological activity of intravitreal VEGF Trap.","volume":"92","author":"Stewart","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"497178","DOI":"10.1155\/2014\/497178","article-title":"Intravitreal aflibercept outcomes in patients with persistent macular exudate previously treated with bevacizumab and\/or ranibizumab for neovascular age-related macular degeneration.","volume":"2014","author":"Griffin","year":"2014","journal-title":"J Ophthalmol"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.4103\/njcp.njcp_696_20","article-title":"Results of the switch from intravitreal ranibizumab to intravitreal aflibercept therapy in patients with neovascular age-related macular degeneration: a 42-month retrospective real-world study.","volume":"24","author":"Ertan","year":"2021","journal-title":"Niger J Clin Pract"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ophtha.2013.08.035","article-title":"Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration.","volume":"121","author":"Chang","year":"2014","journal-title":"Ophthalmology"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2147\/OPTH.S206910","article-title":"Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration.","volume":"13","author":"Koike","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2013.04.009","article-title":"Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.","volume":"156","author":"Schachat","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bjophthalmol-2011-301236","article-title":"Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?","volume":"96","author":"Binder","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ajo.2014.11.022","article-title":"One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration.","volume":"159","author":"Arcinue","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajo.2013.02.017","article-title":"Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.","volume":"156","author":"Bakall","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ophtha.2012.08.008","article-title":"Super-dose anti-VEGF (SAVE) trial: 2.0\u2009mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.","volume":"120","author":"Brown","year":"2013","journal-title":"Ophthalmology"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2016.03.038","article-title":"Long-term results of pro re nata regimen of aflibercept treatment in persistent neovascular age-related macular degeneration.","volume":"167","author":"Muftuoglu","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","article-title":"Effect of high-dose intravitreal aflibercept, 8\u2009mg, in patients with neovascular age-related macular degeneration. The phase 2 CANDELA randomized clinical trial.","volume":"141","author":"Wykoff","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/bjophthalmol-2014-305514","article-title":"Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data.","volume":"99","author":"Barthelmes","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1007\/s00417-019-04456-2","article-title":"Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept.","volume":"257","author":"Hara","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/eye.2014.233","article-title":"Earlier therapeutic effects associated with high dose (2.0\u2009mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration.","volume":"29","author":"Chan","year":"2015","journal-title":"Eye (Lond)"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"e757","DOI":"10.1111\/aos.13157","article-title":"Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration.","volume":"94","author":"Munk","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/eye.2016.208","article-title":"Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents.","volume":"31","author":"Gemenetzi","year":"2017","journal-title":"Eye (Lond)"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4274\/tjo.27448","article-title":"Is there a relationship between use of anti-vascular endothelial growth factor agents and atrophic changes in age-related macular degeneration patients?","volume":"48","author":"Kaynak","year":"2018","journal-title":"Turk J Ophthalmol"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/eye.2011.146","article-title":"Long-term visual outcome of pigment epithelial tears in association with anti-VEGF therapy of pigment epithelial detachment in AMD.","volume":"25","author":"Gutfleisch","year":"2011","journal-title":"Eye (Lond)"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5935\/0004-2749.20210036","article-title":"Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results.","volume":"84","author":"Ertan","year":"2021","journal-title":"Arq Bras Oftalmol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:09:49Z","timestamp":1746317389000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":25,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037839","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,19]]}}}